

On the Horizon Rx

A Humana Healthy Horizons
newsletter for pharmacy providers

Volume I



Updates made to the 2025 state Preferred Drug List

The Oklahoma Health Care Authority (OHCA) continues to operate using a single, state-directed Preferred Drug List (PDL) for all participating managed care organizations and the fee-for-service program, which falls under the state plan within Title XIX of the Social Security Act Medical Assistance Program (Medicaid). The PDL can be found on the Humana For Providers website under the state header for Oklahoma.



Pharmacists as providers for vaccines

The OHCA has a new process for vaccinations at the pharmacy. More information can be found under “Training Materials” on the **OHCA provider training webpage**, specifically at **SoonerCare: Vaccinations at the Pharmacy**.

If you are a pharmacist who is already registered with Oklahoma SoonerSelect as an individual provider and are interested in contracting with Humana’s provider network, please reach out to our provider contracting team by email at **OKProviderDevelopment@humana.com** or call **855-223-9868 (TTY: 711)**, Monday – Friday, 8 a.m. – 5 p.m., Central time.

Humana
Healthy Horizons®
in Oklahoma

Sooner**Select** 

Humana Healthy Horizons in Oklahoma is a Medicaid product of Humana Wisconsin Health Organization Insurance Corporation.

631604OK1224 OKHML8YEN



Updates made to the 2025 medication PAL

Humana Healthy Horizons® in Oklahoma may add or remove prescription drugs on the provider-administered drug preauthorization list (PAL) throughout the year (as directed by OHCA). Humana Healthy Horizons members are notified of negative changes to the PAL by mail.

You can download the latest version, which is the **2025 PAL**, or access historical versions by selecting the Medicaid tab and making your selection on the Humana **Prior authorization and notification lists webpage**. Below are the PAL additions that are effective Jan. 1, 2025.

Brand drug name	Generic drug name	Billing code(s)
Defitelio	defibrotide sodium	C9399, J3490
Dupixent	dupilumab	C9399, J3590
Elrexio	elranatamab-bcmm	J1323
Enspryng	satralizumab-mwge	C9399, J3590
Gattex	teduglutide	C9399, J3490
iDose TR 75mcg intracameral implant	travoprost intracameral implant	J7355
Izervay	avacincaptad pegol intravitreal solution	J2782
Loqtorzi	toripalimab-tpzi	J3263
Ngenla	somatrogon-ghla	C9399, J3590
Nulibry	fosdenopterin	C9399, J3490
Palynziq	pegvaliase-pqpz	C9399, J3590
Pemrydi RTU	pemetrexed	J9324
Pombiliti	cipaglucosidase alfa-atga	J1203
Prevymis IV	letermovir	C9399, J3490
Qalsody	tofersen	J1304
Sogroya	somapacitan-beco	C9399, J3590
Strensiq	asfotase alfa	C9399, J3590
Talvey	talquetamab-tgvs	J3055
Tegsedi	inotersen	C9399, J3490
Udenyca Onbody	pegfilgrastim-cbqv	Q5111
Uptravi	selexipag	C9399, J3490



Concurrent clinical safety alerts help pharmacies see potential risks before dispensing

As part of our enterprise-wide opioid strategy, Humana Healthy Horizons implements concurrent reviews or safety alerts at the point of service to help pharmacies identify and address potentially inappropriate or unsafe drug therapy before dispensing. Your patients may experience medication claim rejections at their pharmacy if impacted. For further details on Humana Healthy Horizons' point-of-sale safety updates, please visit the **latest Humana pharmacy point-of-sale safety edits list** for Medicaid.



Retrospective drug utilization reviews help pharmacies safely dispense prescriptions

Humana Healthy Horizons' Retrospective Drug Utilization Review program supports you in the care of your patients through regular reviews of pharmacy claims data to help detect potentially adverse utilization patterns. You may receive subsequent intervention recommendations by direct mail or fax to alert you to important prescription drug safety issues for your patients. Examples of campaigns include:

- **Asthma inhaled therapy:** Prescribers of patients younger than 12 years old with an asthma diagnosis who may be receiving an inhaled corticosteroid without a short-acting bronchodilator may be notified.
- **Concurrent opioid and gabapentinoid utilizers:** Prescribers of patients with claims for concurrent opioid and high-dose gabapentinoid therapy (gabapentin dose more than 900 mg a day or pregabalin dose more than 450 mg a day) may be notified.
- **Concurrent opioid and benzodiazepine utilizers:** Prescribers of patients with claims for concurrent opioids and benzodiazepines on a regular basis may be notified.
- **Concurrent opioid and antipsychotic utilizers:** Prescribers of patients with claims for concurrent opioids and antipsychotics on a regular basis may be notified.



Medication Therapy Management

Humana Healthy Horizons offers a Medication Therapy Management (MTM) program to support you in ensuring your patients achieve the best possible outcomes from their medications. The MTM program addresses prevalent chronic conditions in Oklahoma, including hypertension, depression and chronic obstructive pulmonary disease, to optimize medication therapy and promote safety through targeted medication reviews (TMRs).

A TMR is an ongoing monitoring process with outreach made to the patient and/or prescriber about a specific or potential medication-related problem, such as adherence, gap in care or drug-drug interaction. Humana Healthy Horizons partners with Outcomes[®] to administer the MTM program. Pharmacies in the Outcomes network can log in to the Outcomes platform to view and complete TMR opportunities for eligible patients.



Improve care and reduce costs

You can improve your care and reduce costs through Humana Healthy Horizons' specialty medication programs. Humana has several specialty programs that promote high-quality care and decrease the costs of specialty medications for our members, notably rare disease case reviews and Utilization Management (UM).

The Rare Disease Case Review Team utilizes a pharmacist-led, in-depth medical record case review process aimed at identifying and mitigating the misuse of high-cost medications for rare and complex diseases.

UM Ultra retrospectively identifies opportunities to decrease specialty medication waste and costs through consolidating dosage forms, switching to a lower-cost generic medication or optimizing dose frequency. Pharmacists fax the member's provider to request a new, cost-saving prescription once an opportunity is identified.

Another strategy we use is through our Smart Maintenance Dosing program. This is a point-of-sale edit for specialty medications with a higher loading dose and lower maintenance dose. The claim will be rejected if dosing is more than the recommended maintenance dose once the loading dose is fulfilled.



Look for general pharmacy news on our webpage

Find pharmacy-related safety alerts, drug recalls, new generic drug announcements and other medication information on the pharmacy news webpage.